Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE (Details 2)

v3.22.1
NOTES PAYABLE (Details 2)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
Equity_Instrument
Dec. 31, 2020
USD ($)
Equity_Instrument
$ / shares
Feb. 29, 2020
Debt Instrument [Line Items]      
Interest rate     10.00%
Principal Outstanding $ 22,339 $ 15,294  
Unamortized Discount 4,332 1,720  
Carrying Amount $ 18,007 $ 13,574  
Shares Underlying Notes | Equity_Instrument 10,173,099 3,946,723  
Principal Outstanding, Current $ 800    
2019 Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Interest rate   10.00%  
Term of Notes   18 months  
Principal Outstanding   $ 7,200  
Unamortized Discount   1,720  
Carrying Amount   $ 5,480  
Shares Underlying Notes | Equity_Instrument   3,630,000  
2019 Convertible Debentures [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares [1]   $ 2.00  
2019 Convertible Debentures [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares [1]   $ 9.52  
Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Principal Outstanding   $ 7,200  
Unamortized Discount   1,720  
Carrying Amount   $ 5,480  
Shares Underlying Notes | Equity_Instrument   3,630,000  
Principal Outstanding, Current   $ 7,200  
Unamortized Discount, Current   1,720  
Convertible Debentures, Current   $ 5,480  
Shares Underlying Notes, Current | Equity_Instrument   3,630,000  
[1] The notes are convertible into Emmaus Life Sciences, Inc. shares. Beginning February 28, 2022, the holder is entitled to call for early redemption, only if the Company’s common stock is not approved for listing on the NYSE American, the Nasdaq Capital Market or other Trading Market (as defined in the agreement). As the Company's common stock is not approved for listing, the notes were classified as current.